02.08.2022 12:38:27
|
IDEXX Laboratories Inc Q2 Income Drops, misses estimates
(RTTNews) - IDEXX Laboratories Inc (IDXX) released a profit for second quarter that decreased from the same period last year and missed the Street estimates.
The company's bottom line came in at $131.98 million, or $1.56 per share. This compares with $202.58 million, or $2.34 per share, in last year's second quarter.
Analysts on average had expected the company to earn $1.64 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 4.2% to $860.55 million from $826.14 million last year.
IDEXX Laboratories Inc earnings at a glance (GAAP) :
-Earnings (Q2): $131.98 Mln. vs. $202.58 Mln. last year. -EPS (Q2): $1.56 vs. $2.34 last year. -Analyst Estimates: $1.64 -Revenue (Q2): $860.55 Mln vs. $826.14 Mln last year.
-Guidance: Full year EPS guidance: $7.77 - $8.05 Full year revenue guidance: $3,305 - $3,385 Mln
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu IDEXX Laboratoriesmehr Nachrichten
03.02.25 |
Schwacher Wochentag in New York: NASDAQ Composite beendet den Handel im Minus (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 verbucht zum Handelsende Verluste (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 zum Ende des Montagshandels schwächer (finanzen.at) | |
03.02.25 |
Verluste in New York: NASDAQ Composite nachmittags in Rot (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 am Montagnachmittag schwächer (finanzen.at) | |
03.02.25 |
Handel in New York: S&P 500 legt den Rückwärtsgang ein (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 präsentiert sich mittags schwächer (finanzen.at) | |
03.02.25 |
Zurückhaltung in New York: NASDAQ Composite mittags in Rot (finanzen.at) |
Analysen zu IDEXX Laboratoriesmehr Analysen
Aktien in diesem Artikel
IDEXX Laboratories | 444,20 | -2,74% |
|